|05/01/17||Forward Pharma CEO to Present at the 42nd Annual Deutsche Bank Health Care Conference on May 4, 2017|
|COPENHAGEN, Denmark, May 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will present at the 42nd Annual Deutsche Bank Health Care Conference, being held May 3-4, 2017 in Boston, MA. Dr. Svendsen will present on Thursday, May 4, at 10:40 AM ET and host one-on-one meetings before and after the presentation.
Investors and other interested parties may access a live audio webcast of our... |
|05/01/17||Forward Pharma Further Aligns Cost Structure with Focus Following Settlement and License Agreement|
|COPENHAGEN, Denmark, May 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward” or the “Company”) today provided an update on the Company’s strategic focus and related initiatives to reduce operating and personnel costs following the Settlement and License Agreement with Biogen.
Consistent with the focus on executing on the intellectual property strategy and the planned timeline for conclusion of ongoing research and development activities, Executive Vice Presidents R... |
|04/18/17||Forward Pharma Reports Fourth Quarter and Year End 2016 Financial and Operational Results|
|COPENHAGEN, Denmark, April 18, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward” or the “Company”), today reported financial results for the fourth quarter and year ended December 31, 2016. Net income for the fourth quarter December 31, 2016 was $9.6 million while net loss for the year ended December 31, 2016 was $33.3 million, or $0.20 and $(0.71) per diluted share, respectively. On a non-GAAP basis, after removing the effect of non-cash income and expense items, our... |
|03/31/17||Forward Pharma Intends to Appeal Decision in Patent Interference Proceeding with Biogen Inc.|
|COPENHAGEN, Denmark, March 31, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (FWP) (“Forward Pharma” or the “Company”), a biopharmaceutical company that commenced development in 2005 of FP187, a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that it intends to file an appeal challenging today’s decision by the Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office (“USPTO”) in Pat... |